Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

CG Oncology (CGON) EBITDA Margin (2023 - 2025)

CG Oncology's EBITDA Margin history spans 3 years, with the latest figure at 2097.33% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 624675.0% year-over-year to 2097.33%; the TTM value through Dec 2025 reached 4722.13%, up 534512.0%, while the annual FY2025 figure was 4722.13%, 534512.0% up from the prior year.
  • EBITDA Margin reached 2097.33% in Q4 2025 per CGON's latest filing, up from 3068.97% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 2097.33% in Q4 2025 to a low of 1935500.0% in Q4 2023.
  • Average EBITDA Margin over 3 years is 228455.68%, with a median of 15817.53% recorded in 2024.
  • Peak YoY movement for EBITDA Margin: soared 192715592bps in 2024, then plummeted -7691409bps in 2025.
  • A 3-year view of EBITDA Margin shows it stood at 1935500.0% in 2023, then skyrocketed by 100bps to 8344.08% in 2024, then skyrocketed by 75bps to 2097.33% in 2025.
  • Per Business Quant, the three most recent readings for CGON's EBITDA Margin are 2097.33% (Q4 2025), 3068.97% (Q3 2025), and 81161.54% (Q1 2025).